Reduced CD44 standard expression is associated with tumour recurrence and unfavourable outcome in differentiated thyroid carcinoma

Reduced CD44 standard expression is associated with tumour recurrence and unfavourable outcome in differentiated thyroid carcinoma

CD44 was detected with an antibody recognizing all forms of CD44 (CD44 standard) and others specific for its v3 and v6 variant isoforms; their prognostic value was evaluated in 213 patients with differentiated thyroid carcinoma (DTC). The staining patterns of CD44 standard (s) and CD44v6 in tumour t...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Journal of pathology 2000-11, Vol.192 (3), p.321-327
Hauptverfasser: Böhm, Jan P., Niskanen, Leo K., Pirinen, Risto T., Kiraly, Kari, Kellokoski, Jari K., Moisio, Kaisa I., Eskelinen, Matti J., Tulla, Harri E., Hollmen, Sinikka, Alhava, Esko M., Kosma, Veli-Matti
Format: Artikel
Sprache:eng
Schlagworte:
Adolescent
Adult
Age Factors
Aged
Aged, 80 and over
Biological and medical sciences
Biomarkers, Tumor
Carcinoma, Papillary, Follicular - immunology
Carcinoma, Papillary, Follicular - secondary
CD44
Child
differentiated thyroid carcinoma
Disease-Free Survival
Endocrinopathies
Female
Humans
Hyaluronan Receptors - immunology
immunohistochemistry
Male
Malignant tumors
Medical sciences
Middle Aged
Multivariate Analysis
Neoplasm Metastasis - immunology
Neoplasm Recurrence, Local - immunology
Prognosis
recurrence
Thyroglobulin - analysis
Thyroid Neoplasms - immunology
Thyroid Neoplasms - pathology
Thyroid Neoplasms - surgery
Thyroid. Thyroid axis (diseases)
Thyroidectomy - methods
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:CD44 was detected with an antibody recognizing all forms of CD44 (CD44 standard) and others specific for its v3 and v6 variant isoforms; their prognostic value was evaluated in 213 patients with differentiated thyroid carcinoma (DTC). The staining patterns of CD44 standard (s) and CD44v6 in tumour tissue were quite similar, 176 cases (83%) being highly positive for CD44s and 153 cases (72%) for CD44v6. Only 18 (9%) tumours showed high expression of CD44v3. Papillary carcinomas were significantly more often high expressors of CD44s and CD44v6 than follicular carcinomas (p
ISSN:0022-3417
1096-9896
DOI:10.1002/1096-9896(2000)9999:9999<::AID-PATH711>3.0.CO;2-1